The Big Question Part II: Is now the time to buy into pharmas?

Greig Bryson Investment director – global equities, SWIP   Clouds are lifting I have been investing in European banks and have been progressively raising the position through the course of this year. The pharmaceutical sector has been operating under a shadow cast by the expiry of key patents for a number of years. However, the clouds are beginning to lift and large parts of the sector are now benefiting from the re-emergence of revenue growth, driven by demographics, demand from emerging markets and new drug discoveries. This revenue growth is translating into higher margins ...